Go-ahead lift for Regenix
Biotech company Tissue Regenix has received European approval to start selling its main product, the dCELL Vascular Patch, which is permanently implanted into the human body for vascular repair.
The York-based group, which was spun out of the University of Leeds, will now seek US approval for the patch.
The company's unique technology, dCELL, removes cells from human and animal body parts to create a scaffold which can be used to replace worn out or diseased body parts, without the need for anti-rejection drugs.
Advertisement
Hide AdAdvertisement
Hide AdThe company believes its technology has the capacity to revolutionise medicine. It raised 4.5m via placing and now has funds of 7.4m, which it will use to develop dCELL, which has applications in vascular, cardiac and orthopaedic medicine.